Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3616 + Abiraterone in mCRPC
NCT05156450Phase 2Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of culmerciclib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by West China Hospital of Sichuan University. Status: unknown.
02
Drugs
culmerciclib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05156450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156450.